Suppr超能文献

在ClinicalTrials.gov注册的细胞治疗试验中结果报告率较低。

Poor Result Reporting Rate in Cell Therapy Trials Registered at ClinicalTrials.gov.

作者信息

Negoro Takaharu, Okura Hanayuki, Hayashi Shigekazu, Arai Tsutomu, Matsuyama Akifumi

机构信息

Center for Reverse Translational Research, Osaka Habikino Medical Center, Osaka Prefectural Hospital Organization, Habikino City, Japan.

Institute of Innovative Medical Technology, Osaka, Japan.

出版信息

Tissue Eng Part B Rev. 2023 Dec;29(6):623-633. doi: 10.1089/ten.TEB.2023.0053. Epub 2023 Jun 7.

Abstract

As research associates in clinical experiments, we have an obligation to disclose clinical methodologies and findings in full transparency in ethics. However, inadequate disclosure in results reporting clinical trials registered on ClinicalTrials.gov has been revealed, with approximately half the trial results not being reported in an applicable manner. Our recent study in clinical trials of regenerative medicine for four kinds of neurological diseases revealed that the rate of result reporting to ClinicalTrials.gov is inadequate for gene and cell therapy (CT) trials. In this path, further curiosity emerged to see what the findings would be if the analysis was conducted for trials in all disease areas, and outcomes if gene therapy (GT) and CT were distinguished in terms. In this study, the scope of analysis was further expanded to include all disease areas, and the drug classification from the AdisInsight database was used for modality classification, with biologic drug trials classified as controls, CT, GT, and GT. To begin, among all interventional clinical trials with registration in the ClinicalTrials.gov registry and with a primary completion between 2010 and 2019, we created a total of 5539 datasets corresponding to trials classified as GT and CT, while biologics (BLG) as controls in the AdisInsight drug classification. The status of reported results of these trials was identified by surveying posting status of ClinicalTrials.gov and publication in journals (PubMed), respectively. Based on the obtained dataset, multivariate analysis was performed on the data on the reporting rate of clinical trial results, aggregated by sponsor, phase, status, and modality (CT, GT, GT, and BLG), respectively. The result shows that CT was identified as an independent factor restraining result reporting ratio in both ClinicalTrials.gov and total disclosures, whereas GT as boosting result reporting ratio. Since the result reporting rate of CT results was notably poor, we discussed the causes and solutions in this regard.

摘要

作为临床实验中的研究助理,我们有义务在伦理方面完全透明地披露临床方法和研究结果。然而,已发现ClinicalTrials.gov上注册的临床试验结果报告存在披露不足的情况,约有一半的试验结果未以适用的方式报告。我们最近对四种神经系统疾病的再生医学临床试验进行的研究表明,向ClinicalTrials.gov报告结果的比率在基因和细胞疗法(CT)试验中不足。在这条道路上,人们进一步好奇,如果对所有疾病领域的试验进行分析,以及如果在术语上区分基因疗法(GT)和CT,结果会是什么。在本研究中,分析范围进一步扩大到包括所有疾病领域,并使用来自AdisInsight数据库的药物分类进行模式分类,生物药物试验分为对照、CT、GT和GT。首先,在ClinicalTrials.gov注册且主要完成时间在2010年至2019年之间的所有介入性临床试验中,我们总共创建了5539个数据集,对应于分类为GT和CT的试验,而在AdisInsight药物分类中,生物制剂(BLG)作为对照。通过分别调查ClinicalTrials.gov的发布状态和期刊(PubMed)上的发表情况,确定了这些试验报告结果的状态。基于获得的数据集,分别按申办者、阶段、状态和模式(CT、GT、GT和BLG)对临床试验结果报告率的数据进行了多变量分析。结果表明,在ClinicalTrials.gov和总披露中,CT均被确定为抑制结果报告率的独立因素,而GT则提高了结果报告率。由于CT结果的报告率明显较差,我们讨论了这方面的原因和解决方案。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验